We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
Read MoreHide Full Article
Intuitive Surgical Inc. (ISRG - Free Report) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20. Last quarter, the company’s earnings exceeded the Zacks Consensus Estimate by 17.63%. Also, the company delivered an average beat of 14.44% in the trailing four quarters.
Let’s see how things are shaping up for Intuitive Surgical prior to this announcement.
Factors at Play
We believe that the growing adoption of Intuitive Surgical’s da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key catalyst. Earlier, da Vinci procedures increased approximately 18% year over year in the first quarter of 2017. For the second quarter, the company expects procedure growth rate to slow down a bit outside the U.S. The company anticipates full-year 2017 procedure growth within 12% to 14%. Full-year 2017 gross profit margin is expected in the upper end of the range of 69% to 71% of net revenue.
Moreover, rising procedural volumes outside the U.S., particularly in Europe, fortifies the company’s market position. In fact, the integrated Table Motion product line has gained significant traction within a short span of time and is likely to boost the company’s top line in the to-be-reported quarter. Meanwhile, increased spending on product development and higher investments in expanding the company’s footprint in international markets are prudent moves to drive long-term growth in our view.
We note that Intuitive Surgical outperformed the Zacks Medical Instruments sub-industry in the last one year. While the stock has returned 41.11%, the sub-industry has gained only 10.08%.
Intuitive Surgical, Inc. Price, Consensus and EPS Surprise
Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Intuitive Surgical’s Earnings ESP is 0.00% since both the Most Accurate estimate and the Zacks Consensus Estimate stand at $4.86. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intuitive Surgical has a Zacks Rank #3. Though a favorable Zacks Rank increases the predictive power of ESP, the company’s ESP of 0.00% makes surprise prediction difficult.
Also, we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter:
Dextera Surgical Inc. has an Earnings ESP of +9.09% and holds a Zacks Rank #2.
Telefex Incorporated (TFX - Free Report) has an Earnings ESP of +1.06% and carries a Zacks Rank #2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
Intuitive Surgical Inc. (ISRG - Free Report) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20. Last quarter, the company’s earnings exceeded the Zacks Consensus Estimate by 17.63%. Also, the company delivered an average beat of 14.44% in the trailing four quarters.
Let’s see how things are shaping up for Intuitive Surgical prior to this announcement.
Factors at Play
We believe that the growing adoption of Intuitive Surgical’s da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key catalyst. Earlier, da Vinci procedures increased approximately 18% year over year in the first quarter of 2017. For the second quarter, the company expects procedure growth rate to slow down a bit outside the U.S. The company anticipates full-year 2017 procedure growth within 12% to 14%. Full-year 2017 gross profit margin is expected in the upper end of the range of 69% to 71% of net revenue.
Moreover, rising procedural volumes outside the U.S., particularly in Europe, fortifies the company’s market position. In fact, the integrated Table Motion product line has gained significant traction within a short span of time and is likely to boost the company’s top line in the to-be-reported quarter. Meanwhile, increased spending on product development and higher investments in expanding the company’s footprint in international markets are prudent moves to drive long-term growth in our view.
We note that Intuitive Surgical outperformed the Zacks Medical Instruments sub-industry in the last one year. While the stock has returned 41.11%, the sub-industry has gained only 10.08%.
Intuitive Surgical, Inc. Price, Consensus and EPS Surprise
Intuitive Surgical, Inc. Price, Consensus and EPS Surprise | Intuitive Surgical, Inc. Quote
Earnings Whispers
Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Intuitive Surgical’s Earnings ESP is 0.00% since both the Most Accurate estimate and the Zacks Consensus Estimate stand at $4.86. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intuitive Surgical has a Zacks Rank #3. Though a favorable Zacks Rank increases the predictive power of ESP, the company’s ESP of 0.00% makes surprise prediction difficult.
Also, we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter:
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of 0.44% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Dextera Surgical Inc. has an Earnings ESP of +9.09% and holds a Zacks Rank #2.
Telefex Incorporated (TFX - Free Report) has an Earnings ESP of +1.06% and carries a Zacks Rank #2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>